PCN124 - Cost Effectiveness Analysis of Exemestane Versus Capecitabine Monotherapy for Patients with Hormone Receptor–Positive and Her2-Negative, Metastatic Breast Cancer from National Cancer Institute Prespective in Egypt

Autor: Abdallah, H, Abourawash, AS, Elgazzar, M, Helal, A
Zdroj: In Value in Health October-November 2017 20(9):A434-A434
Databáze: ScienceDirect
Externí odkaz: